Vol. 1 No. 1 (2022): Vol 1 Issue 1 2022

Articles

• Target Validation Before First-in-Human: What Preclinical Packages Systematically Omit

  Janis Grinbergs, Josefine Damsgaard, Kolbeinn Snaebjornsdottir (Author)

  1-9

  • pdf

• Dose Optimisation in Early Oncology Trials: Moving Beyond the Maximum Tolerated Dose

  Trine Holmstrup, Barnaby Hollingbery, Dorottya Csomor (Author)

  10-18

  • pdf

• Patient-Derived Organoids as a Predictive Assay: Concordance With Clinical Response in Colorectal Cancer

  Rodrigo Ochandiano, Daria Fratila, Klara Sjunnesson (Author)

  19-27

  • pdf

• Drug Repurposing From Real-World Prescribing Data: Signal Generation and Its False Positives

  Ruairi Furlong, Denisa Zvarik, Julita Szczepankiewicz (Author)

  28-36

  • pdf

• Antisense Oligonucleotide Therapy for an Ultra-Rare Neurological Variant: A Case Report

  Marc Reuland, Clemence Vaillancour, Villads Kjaergaard-Lund (Author)

  37-45

  • pdf

• Biomarker Qualification Pathways: A Perspective on Why Promising Markers Stall Before Regulatory Acceptance

  Elina Lapina, Fabienne Baumberger, Dario Sciarretta (Author)

  46-55

  • pdf

• Blood-Brain Barrier Penetration in Preclinical Screening: A Short Communication on Assay Discordance

  Marc Kremer-Diss, Grigoris Stergiadis, Andreas Loizidou (Author)

  56-64

  • pdf